<html><head></head><body><h1>Timolol (Systemic)</h1><p class="drug-subtitle"><b>Class:</b> beta-Adrenergic Blocking Agents<br/>
<b>VA Class:</b> CV100<br/>
<b>CAS Number:</b> 26921-17-5<br/></p><ul class="ddc-anchor-links"><li>Uses</li>
<li>Dosage</li>
<li>Cautions</li>
<li>Interactions</li>
<li>Pharmacokinetics</li>
<li>Patient advice</li>
<li>Preparations</li></ul><h2>Introduction</h2><p>Nonselective β-adrenergic blocking agent (β-blocker).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="uses">Uses for Timolol (Systemic)</h2><h3>Hypertension</h3><p>Management of hypertension (alone or in combination with other classes of antihypertensive agents).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1200&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>β-Blockers generally not preferred for first-line therapy of hypertension according to current evidence-based hypertension guidelines, but may be considered in patients who have a compelling indication (e.g., prior MI, ischemic heart disease, heart failure) for their use or as add-on therapy in those who do not respond adequately to the preferred drug classes (ACE inhibitors, angiotensin II receptor antagonists, calcium-channel blockers, or thiazide diuretics).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;194&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;501&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;502&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;503&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;504&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;515&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;523&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;524&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;527&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;800&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1200&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Timolol is one of several β-blockers (including bisoprolol, carvedilol, metoprolol succinate, metoprolol tartrate, nadolol, and propranolol) recommended by a 2017 ACC/AHA multidisciplinary hypertension guideline as first-line therapy for hypertension in patients with stable ischemic heart disease/angina.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1200&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Individualize choice of therapy; consider patient characteristics (e.g., age, ethnicity/race, comorbidities, cardiovascular risk) as well as drug-related factors (e.g., ease of administration, availability, adverse effects, cost).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;501&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;502&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;503&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;504&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;515&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1200&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1201&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>The 2017 ACC/AHA hypertension guideline classifies BP in adults into 4 categories: normal, elevated, stage 1 hypertension, and stage 2 hypertension.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1200&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Table 1.)</p><p>Source: Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Hypertension</i>. 2018;71:e13-115.</p><p>Individuals with SBP and DBP in 2 different categories (e.g., elevated SBP and normal DBP) should be designated as being in the higher BP category (i.e., elevated BP).</p><p>Category</p><p>SBP (mm Hg)</p><p>DBP (mm Hg)</p><p>Normal</p><p>&lt;120</p><p>and</p><p>&lt;80</p><p>Elevated</p><p>120–129</p><p>and</p><p>&lt;80</p><p>Hypertension, Stage 1</p><p>130–139</p><p>or</p><p>80–89</p><p>Hypertension, Stage 2</p><p>≥140</p><p>or</p><p>≥90</p><p>The goal of hypertension management and prevention is to achieve and maintain optimal control of BP.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1200&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; However, the BP thresholds used to define hypertension, the optimum BP threshold at which to initiate antihypertensive drug therapy, and the ideal target BP values remain controversial.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;501&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;503&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;504&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;505&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;506&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;507&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;508&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;515&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;523&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;530&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1200&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1201&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1207&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1209&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1222&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1223&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1229&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>The 2017 ACC/AHA hypertension guideline generally recommends a target BP goal (i.e., BP to achieve with drug therapy and/or nonpharmacologic intervention) &lt;130/80 mm Hg in all adults regardless of comorbidities or level of atherosclerotic cardiovascular disease (ASCVD) risk.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1200&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; In addition, an SBP goal of &lt;130 mm Hg generally is recommended for noninstitutionalized ambulatory patients ≥65 years of age with an average SBP of ≥130 mm Hg.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1200&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; These BP goals are based upon clinical studies demonstrating continuing reduction of cardiovascular risk at progressively lower levels of SBP.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1200&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1202&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1210&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Other hypertension guidelines generally have based target BP goals on age and comorbidities.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;501&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;504&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;536&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Guidelines such as those issued by the JNC 8 expert panel generally have targeted a BP goal of &lt;140/90 mm Hg regardless of cardiovascular risk and have used higher BP thresholds and target BPs in elderly patients&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;501&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;504&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;536&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; compared with those recommended by the 2017 ACC/AHA hypertension guideline.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1200&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Some clinicians continue to support previous target BPs recommended by JNC 8 due to concerns about the lack of generalizability of data from some clinical trials (e.g., SPRINT study) used to support the 2017 ACC/AHA hypertension guideline and potential harms (e.g., adverse drug effects, costs of therapy) versus benefits of BP lowering in patients at lower risk of cardiovascular disease.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1222&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1223&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1224&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1229&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Consider potential benefits of hypertension management and drug cost, adverse effects, and risks associated with the use of multiple antihypertensive drugs when deciding a patient's BP treatment goal.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1200&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1220&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1229&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>For decisions regarding when to initiate drug therapy (BP threshold), the 2017 ACC/AHA hypertension guideline incorporates underlying cardiovascular risk factors.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1200&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1207&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; ASCVD risk assessment is recommended by ACC/AHA for all adults with hypertension.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1200&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>ACC/AHA currently recommend initiation of antihypertensive drug therapy in addition to lifestyle/behavioral modifications at an SBP ≥140 mm Hg or DBP ≥90 mm Hg in adults who have no history of cardiovascular disease (i.e., <i>primary prevention</i>) and a low ASCVD risk (10-year risk &lt;10%).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1200&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>For <i>secondary prevention</i> in adults with known cardiovascular disease or for <i>primary prevention</i> in those at higher risk for ASCVD (10-year risk ≥10%), ACC/AHA recommend initiation of antihypertensive drug therapy at an average SBP ≥130 mm Hg or an average DBP ≥80 mm Hg.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1200&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Adults with hypertension and diabetes mellitus, chronic kidney disease (CKD), or age ≥65 years are assumed to be at high risk for cardiovascular disease; ACC/AHA state that such patients should have antihypertensive drug therapy initiated at a BP ≥130/80 mm Hg.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1200&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Individualize drug therapy in patients with hypertension and underlying cardiovascular or other risk factors.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;502&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1200&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>In stage 1 hypertension, experts state that it is reasonable to initiate drug therapy using the stepped-care approach in which one drug is initiated and titrated and other drugs are added sequentially to achieve the target BP.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1200&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Initiation of antihypertensive therapy with 2 first-line agents from different pharmacologic classes recommended in adults with stage 2 hypertension and average BP &gt;20/10 mm Hg above BP goal.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1200&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Black hypertensive patients generally tend to respond better to monotherapy with calcium-channel blockers or thiazide diuretics than to β-blockers.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;176&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;180&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;181&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;501&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;504&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1200&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; However, diminished response to β-blockers is largely eliminated when administered concomitantly with a thiazide diuretic.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;500&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>MI</h3><p>Secondary prevention following acute MI.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Administration within 7–28 days following MI associated with reductions in cardiovascular mortality and nonfatal reinfarction.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Experts recommend β-blocker therapy in all patients with left ventricular systolic dysfunction and prior MI; a β-blocker with proven mortality benefit (bisoprolol, carvedilol, or metoprolol succinate) is preferred.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;525&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Although benefits of long-term β-blockade in patients with normal left ventricular function are less well established, experts recommend continuing β-blocker therapy for at least 3 years in such patients.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;525&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Vascular Headache</h3><p>Prophylaxis of common or classic migraine headache.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;106&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;107&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;108&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;110&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;127&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;128&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Chronic Stable Angina</h3><p>Has been used in the management of chronic stable angina pectoris†.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>β-Blockers are recommended as first-line anti-ischemic drugs in most patients with chronic stable angina; despite differences in cardioselectivity, intrinsic sympathomimetic activity, and other clinical factors, all β-blockers appear to be equally effective for this use.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1101&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="dosage">Timolol (Systemic) Dosage and Administration</h2><h3>General</h3><ul>
<li>
<p>Monitor reductions in heart rate and BP as a guide for determining optimum dosage.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>If long-term therapy is discontinued, reduce dosage gradually over a period of 1–2 weeks.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Abrupt Withdrawal of Therapy under Cautions.)</p>
</li>
</ul><p>Monitor reductions in heart rate and BP as a guide for determining optimum dosage.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If long-term therapy is discontinued, reduce dosage gradually over a period of 1–2 weeks.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Abrupt Withdrawal of Therapy under Cautions.)</p><ul>
<li>
<p>Monitor BP regularly (i.e., monthly) during therapy and adjust dosage of the antihypertensive drug until BP controlled.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1200&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>If unacceptable adverse effects occur, discontinue drug and initiate another antihypertensive agent from a different pharmacologic class.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1216&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>If adequate BP response not achieved with a single antihypertensive agent, either increase dosage of single drug or add a second drug with demonstrated benefit and preferably a complementary mechanism of action (e.g., ACE inhibitor, angiotensin II receptor antagonist, calcium-channel blocker, thiazide diuretic).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1200&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1216&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Many patients will require ≥2 drugs from different pharmacologic classes to achieve BP goal; if goal BP still not achieved, add a third drug.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1200&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1216&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>Monitor BP regularly (i.e., monthly) during therapy and adjust dosage of the antihypertensive drug until BP controlled.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1200&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If unacceptable adverse effects occur, discontinue drug and initiate another antihypertensive agent from a different pharmacologic class.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1216&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If adequate BP response not achieved with a single antihypertensive agent, either increase dosage of single drug or add a second drug with demonstrated benefit and preferably a complementary mechanism of action (e.g., ACE inhibitor, angiotensin II receptor antagonist, calcium-channel blocker, thiazide diuretic).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1200&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1216&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Many patients will require ≥2 drugs from different pharmacologic classes to achieve BP goal; if goal BP still not achieved, add a third drug.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1200&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1216&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Administration</h3><p>Administer orally, usually twice daily.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>For management of hypertension, once-daily dosing may be possible in some patients.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>In patients with chronic stable angina pectoris†, administer orally in 3 or 4 divided doses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>During maintenance therapy in patients with vascular headaches (migraine), may administer daily dosage as a single rather than divided dose.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Dosage</h3><p>Available as timolol maleate; dosage expressed in terms of the salt.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Initially, 10 mg twice daily, either alone or in combination with a diuretic.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Increase dosage gradually at weekly (or longer) intervals until optimum effect is obtained.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Usual maintenance dosage is 20–40 mg daily, given in 2 divided doses; once-daily dosing may be possible in some patients.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Increases up to a maximum of 60 mg daily (given in 2 divided doses) may be necessary.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Secondary prevention after acute phase of MI: Usual dosage is 10 mg twice daily.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Optimal duration of therapy for secondary prevention remains to be established.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;527&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;802&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;804&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Experts generally recommend long-term therapy in post-MI patients with left ventricular dysfunction, and at least 3 years of therapy in those with normal left ventricular function.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;525&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;802&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;804&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1101&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>15–45 mg daily, given in 3 or 4 divided doses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Adjust dosage according to clinical response and to maintain a resting heart rate of 55–60 bpm.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Initially, 10 mg twice daily.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;107&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;108&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;110&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Adjust dosage according to clinical response and patient tolerance; do not exceed 30 mg daily, given in divided doses (e.g., 10 mg in the morning and 20 mg in the evening).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;108&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>During maintenance therapy, can administer 20-mg daily dosage as a single rather than divided dose; some patients may respond adequately to 10 mg once daily.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If an adequate response is not achieved after 6–8 weeks at the maximum recommended dosage, discontinue therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Prescribing Limits</h3><p>Maximum 60 mg daily.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Maximum 30 mg daily.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;108&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Special Populations</h3><p>Must modify doses and/or frequency of administration in response to degree of hepatic impairment.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Must modify doses and/or frequency of administration in response to degree of renal impairment.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Select dosage with caution because of age-related decreases in hepatic, renal, and/or cardiac function and concomitant disease and drug therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Initiate at low end of dosing range.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="cautions">Cautions for Timolol (Systemic)</h2><h3>Contraindications</h3><ul>
<li>
<p>Known hypersensitivity to timolol or any ingredient in the formulation.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Bronchial asthma (or a history of bronchial asthma), allergic bronchospasm, or severe COPD.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Severe bradycardia, heart block greater than first degree, overt cardiac failure, or cardiogenic shock.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>Known hypersensitivity to timolol or any ingredient in the formulation.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Bronchial asthma (or a history of bronchial asthma), allergic bronchospasm, or severe COPD.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Severe bradycardia, heart block greater than first degree, overt cardiac failure, or cardiogenic shock.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Warnings/Precautions</h3><p>Possible precipitation of heart failure.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Avoid use in patients with overt heart failure; may use cautiously in patients with inadequate myocardial function and, if necessary, in patients with well-compensated heart failure (e.g., those controlled with cardiac glycosides and/or diuretics).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Adequate treatment (e.g., with a cardiac glycoside and/or diuretic) and close observation recommended if signs or symptoms of impending heart failure occur; if heart failure continues, discontinue therapy, gradually if possible.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Abrupt withdrawal of therapy is not recommended as it may exacerbate angina symptoms or precipitate MI in patients with coronary artery disease.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Gradually decrease dosage over a period of 1–2 weeks and monitor patients carefully; advise patients to temporarily limit their physical activity during withdrawal of therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If exacerbation of angina occurs or acute coronary insufficiency develops, reinstitute therapy promptly, at least temporarily, and initiate appropriate measures for management of unstable angina pectoris.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Possible inhibition of bronchodilation produced by endogenous catecholamines.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Generally should not be used in patients with bronchospastic disease, but may use with caution in patients who do not respond to or cannot tolerate alternative treatment.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Use with caution in patients with nonallergic bronchospasm (e.g., chronic bronchitis, emphysema) or a history of nonallergic bronchospasm.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Contraindications under Cautions.)</p><p>Possible increased risks associated with general anesthesia (e.g., severe hypotension, difficulty restarting or maintaining heart beat) due to decreased ability of the heart to respond to reflex β-adrenergic stimuli.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Some clinicians recommend gradual withdrawal before elective surgery.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Manufacturers recommend administration of β-agonists (e.g., dopamine, dobutamine, isoproterenol) to reverse β-adrenergic blockade if necessary during surgery.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Possible decreased signs and symptoms of hypoglycemia (e.g., tachycardia, but not sweating or dizziness).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Use with caution in patients with diabetes mellitus receiving hypoglycemic drugs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>May mask signs of hyperthyroidism (e.g., tachycardia).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Possible thyroid storm if therapy is abruptly withdrawn; carefully monitor patients having or suspected of developing thyrotoxicosis.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Patients with a history of atopy or anaphylactic reactions to a variety of allergens may be more reactive to repeated, accidental, diagnostic, or therapeutic challenges with such allergens while taking β-blocking agents; such patients may be unresponsive to usual doses of epinephrine.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>β-Adrenergic blockade reported to potentiate muscle weakness consistent with certain myasthenic symptoms (e.g., diplopia, ptosis, generalized weakness).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Increased muscle weakness reported rarely in some patients with myasthenia gravis or myasthenic symptoms.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Possible cardiovascular effects (e.g., hypotension, bradycardia) that can adversely affect cerebral blood flow.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Use with caution in patients with cerebrovascular insufficiency.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If signs or symptoms suggestive of reduced cerebral blood flow occur, consider discontinuance.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Shares the toxic potentials of β-blockers; observe usual precautions of these agents.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Category C.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Distributed into milk.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Discontinue nursing or the drug.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Safety and efficacy not established.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Insufficient experience in patients ≥65 years of age to determine whether geriatric patients respond differently than younger adults.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Substantially eliminated by the kidneys; assess renal function periodically and adjust dosage since geriatric patients are more likely to have decreased renal function.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Geriatric Patients under Dosage and Administration.)</p><p>Use with caution; dosage adjustment may be necessary.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Hepatic Impairment under Dosage and Administration.)</p><p>Use with caution; dosage adjustment may be necessary.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Renal Impairment under Dosage and Administration.)</p><h3>Common Adverse Effects</h3><p>Fatigue, headache, bradycardia, arrhythmia, pruritus, dizziness, dyspnea, eye irritation.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="interactions">Interactions for Timolol (Systemic)</h2><p>Appears to be metabolized partly by CYP2D6.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;540&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Drugs Affecting Hepatic Microsomal Enzymes</h3><p>CYP2D6 inhibitors: Potential pharmacodynamic (increased β-adrenergic blockade) and pharmacokinetic interaction (increased plasma timolol concentrations).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;540&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Specific Drugs</h3><p>Drug</p><p>Interaction</p><p>Comments</p><p>Calcium-channel blocking agents</p><p>Potential hypotension, AV conduction disturbances, and left ventricular failure&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Avoid concomitant use in patients with impaired cardiac function&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Clonidine</p><p>β-Adrenergic blockade may exacerbate rebound hypertension which may occur following clonidine discontinuance&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;145&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;146&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Discontinue β-blockers several days before gradual withdrawal of clonidine&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;145&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;146&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If clonidine therapy is to be replaced by a β-blocker, delay administration for several days after clonidine discontinuance&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;145&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;146&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Digoxin</p><p>Possible additive effect in prolonging AV conduction time when used concomitantly with diltiazem or verapamil&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Hypotensive agents (hydralazine, methyldopa)</p><p>Possible increased hypotensive effect&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Careful dosage adjustment is recommended&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>NSAIAs</p><p>Potential blunting of hypotensive effects&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Monitor patients carefully&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Quinidine</p><p>Possible potentiation of β-adrenergic blockade (e.g., decreased heart rate)&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Reserpine</p><p>Possible additive effects&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Observe closely for evidence of marked bradycardia or hypotension (may be manifested as vertigo, presyncope or syncope, or orthostatic changes in BP without compensatory tachycardia)&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="pharmacokinetics">Timolol (Systemic) Pharmacokinetics</h2><h3>Absorption</h3><p>Absorption from GI tract is rapid; approximately 90% absorbed following oral administration.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Peak plasma concentration usually attained within 1–2 hours.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Distribution</h3><p>Distributed into milk.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>10–60%, depending on assay method employed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Elimination</h3><p>Approximately 80% metabolized in the liver to inactive metabolites.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Excreted in urine as unchanged drug and metabolites.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>3–4 hours.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Only small amounts removed by hemodialysis.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2>Stability</h2><h3>Storage</h3><p>Tight containers at 15–30°C.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Protect from light.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2>Actions</h2><ul>
<li>
<p>Inhibits response to adrenergic stimuli by competitively blocking β-adrenergic receptors within the myocardium (β<sub>1</sub>-receptors) and bronchial and vascular smooth muscle (β<sub>2</sub>-receptors).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Decreases resting and exercise-stimulated heart rate and reflex orthostatic tachycardia; slows conduction in the AV node; slightly reduces cardiac output, probably secondary to its effect on heart rate.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>No intrinsic sympathomimetic activity or membrane-stabilizing effect on the heart.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Suppresses plasma renin activity and suppresses the renin-aldosterone-angiotensin system.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Reduces BP by decreasing cardiac output, decreasing sympathetic outflow from the CNS, and/or suppressing renin release.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Increases airway resistance.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>Inhibits response to adrenergic stimuli by competitively blocking β-adrenergic receptors within the myocardium (β<sub>1</sub>-receptors) and bronchial and vascular smooth muscle (β<sub>2</sub>-receptors).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Decreases resting and exercise-stimulated heart rate and reflex orthostatic tachycardia; slows conduction in the AV node; slightly reduces cardiac output, probably secondary to its effect on heart rate.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>No intrinsic sympathomimetic activity or membrane-stabilizing effect on the heart.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Suppresses plasma renin activity and suppresses the renin-aldosterone-angiotensin system.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Reduces BP by decreasing cardiac output, decreasing sympathetic outflow from the CNS, and/or suppressing renin release.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Increases airway resistance.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="patient-advice">Advice to Patients</h2><ul>
<li>
<p>Importance of taking timolol exactly as prescribed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of not interrupting or discontinuing therapy without consulting clinician;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; advise patients to temporarily limit physical activity when discontinuing therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of immediately informing clinician at the first sign or symptom of impending heart failure (e.g., weight gain, increased shortness of breath) or if any difficulty in breathing occurs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>In patients with heart failure, importance of informing clinician of signs or symptoms of exacerbation (e.g., weight gain, difficulty in breathing).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of patients informing anesthesiologist or dentist that they are receiving timolol therapy prior to undergoing major surgery.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as concomitant illnesses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of informing patients of other important precautionary information.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Cautions.)</p>
</li>
</ul><p>Importance of taking timolol exactly as prescribed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of not interrupting or discontinuing therapy without consulting clinician;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; advise patients to temporarily limit physical activity when discontinuing therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of immediately informing clinician at the first sign or symptom of impending heart failure (e.g., weight gain, increased shortness of breath) or if any difficulty in breathing occurs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>In patients with heart failure, importance of informing clinician of signs or symptoms of exacerbation (e.g., weight gain, difficulty in breathing).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of patients informing anesthesiologist or dentist that they are receiving timolol therapy prior to undergoing major surgery.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as concomitant illnesses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of informing patients of other important precautionary information.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Cautions.)</p><h2 class="ddc-anchor-offset" id="preparations">Preparations</h2><p><i>Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.</i></p><p><i>Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.</i></p><p>* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name</p><p>Routes</p><p>Dosage Forms</p><p>Strengths</p><p>Brand Names</p><p>Manufacturer</p><p>Oral</p><p>Tablets</p><p>5 mg*</p><p>Timolol Maleate Tablets</p><p>10 mg*</p><p>Timolol Maleate Tablets</p><p>20 mg*</p><p>Timolol Maleate Tablets</p><p>AHFS<sup></sup> DI Essentials™. © Copyright 2021, Selected Revisions February 25, 2019. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.</p><p>† Use is not currently included in the labeling approved by the US Food and Drug Administration.</p><h2>References</h2><p>101. Moser M. Initial treatment of adult patients with essential hypertension: I. Why conventional stepped-care therapy of hypertension is still indicated. <i>Pharmacotherapy</i>. 1985; 5:189-95. http://www.ncbi.nlm.nih.gov/pubmed/2863806?dopt=AbstractPlus</p><p>102. Kaplan NM. Initial treatment of adult patients with essential hypertension: II. Alternating monotherapy is the preferred treatment. <i>Pharmacotherapy</i>. 1985; 5:195-200. http://www.ncbi.nlm.nih.gov/pubmed/4034407?dopt=AbstractPlus</p><p>103. Anon. Drugs for hypertension. <i>Med Lett Drugs Ther</i>. 1984; 26:107-12. http://www.ncbi.nlm.nih.gov/pubmed/6150424?dopt=AbstractPlus</p><p>104. Hyman D, Kaplan NM. Treatment of patients with mild hypertension. <i>Hypertension</i>. 1985; 7:165-70. http://www.ncbi.nlm.nih.gov/pubmed/3884501?dopt=AbstractPlus</p><p>105. Weber MA. Beta blockers in the initial therapy of hypertension. <i>Drug Ther</i>. 1980; 10(11):77-80.</p><p>106. Briggs RS, Millac PA. Timolol in migraine prophylaxis. <i>Headache</i>. 1979; 19:379-81. http://www.ncbi.nlm.nih.gov/pubmed/511540?dopt=AbstractPlus</p><p>107. Tfelt-Hansen P, Standnes B. Timolol vs propranolol vs placebo in common migraine prophylaxis: a double-blind multicenter trial. <i>Acta Neurol Scand</i>. 1984; 69:1-8. http://www.ncbi.nlm.nih.gov/pubmed/6367336?dopt=AbstractPlus</p><p>108. Stellar S, Ahrens SP, Meibohm AR et al. Migraine prevention with timolol: a double-blind crossover study. <i>JAMA</i>. 1984; 252:2576-80. http://www.ncbi.nlm.nih.gov/pubmed/6387197?dopt=AbstractPlus</p><p>110. Andersson KE, Vinge E. β-Adrenergic blockers and calcium antagonists in the prophylaxis and treatment of migraine. <i>Drugs</i>. 1990; 39:355-73. http://www.ncbi.nlm.nih.gov/pubmed/1970289?dopt=AbstractPlus</p><p>111. Merck &amp; Co. Blocadren<sup></sup> (timolol maleate) tablets prescribing information. Whitehouse Station, NJ; 2001 Apr.</p><p>112. American College of Cardiology and American Heart Association. ACC/AHA guidelines for the early management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee to Develop Guidelines for the Early Management of Patients with Acute Myocardial Infarction). <i>Circulation</i>. 1990; 82:664-707. http://www.ncbi.nlm.nih.gov/pubmed/2197021?dopt=AbstractPlus</p><p>113. Roque F, Amuchastegui LM, Lopez Morillos MA et al. The TIARA Study Group. Beneficial effects of timolol on infarct size and late ventricular tachycardia in patients with acute myocardial infarction. <i>Circulation</i>. 1987; 76:610-7. http://www.ncbi.nlm.nih.gov/pubmed/3304706?dopt=AbstractPlus</p><p>114. Goldman L, Sia STB, Cook EF et al. Costs and effectiveness of routine therapy with long-term beta-adrenergic antagonists after acute myocardial infarction. <i>N Engl J Med</i>. 1988; 319:152-7. http://www.ncbi.nlm.nih.gov/pubmed/2898733?dopt=AbstractPlus</p><p>115. Yusuf S, Peto R, Lewis J et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. <i>Prog Cardiovasc Dis</i>. 1985; 27:335-71. http://www.ncbi.nlm.nih.gov/pubmed/2858114?dopt=AbstractPlus</p><p>116. Yusuf S, Sleight P, Held P et al. Routine medical management of acute myocardial infarction: lessons from overviews of recent randomized controlled trials. <i>Circulation</i>. 1990; 82(Suppl 11):11-117-34.</p><p>117. Held P, Yusuf S. Early intravenous beta-blockade in acute myocardial infarction. <i>Cardiology</i>. 1989; 76:132-43. http://www.ncbi.nlm.nih.gov/pubmed/2568179?dopt=AbstractPlus</p><p>118. Pedersen TR for the Norwegian Multicenter Study Group. Six-year follow-up of the Norwegian multicenter study on timolol after acute myocardial infarction. <i>N Engl J Med</i>. 1985; 313:1055-8. http://www.ncbi.nlm.nih.gov/pubmed/2864634?dopt=AbstractPlus</p><p>119. Pedersen TR. The Norwegian multicenter study of timolol after myocardial infarction. <i>Circulation</i>. 1983; 67(Suppl 1):49-53.</p><p>120. The Beta-Blocker Pooling Project Research Group. The Beta-Blocker Pooling Project (BBPP): subgroup findings from randomized trials in post infarction patients. <i>Eur Heart J</i>. 1988; 9(Suppl 1):8-16.</p><p>121. β-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction: I. Mortality results. <i>JAMA</i>. 1982; 247(Suppl 12):1707-14. http://www.ncbi.nlm.nih.gov/pubmed/7038157?dopt=AbstractPlus</p><p>122. The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. <i>N Engl J Med</i>. 1981; 304(Suppl 14):801-7. http://www.ncbi.nlm.nih.gov/pubmed/7010157?dopt=AbstractPlus</p><p>123. Gheorghiade M, Schultz L, Tilley B et al. Effects of propranolol in non-Q-wave acute myocardial infarction in the beta blocker heart attack trial. <i>Am J Cardiol</i>. 1990; 66:129-33. http://www.ncbi.nlm.nih.gov/pubmed/2196771?dopt=AbstractPlus</p><p>124. Yusuf S, Wittes J, Probstfield J. Evaluating effects of treatment in subgroups of patients with a clinical trial: the case of non-Q-wave myocardial infarction and beta blockers. <i>Am J Cardiol</i>. 1990; 66:220-2. http://www.ncbi.nlm.nih.gov/pubmed/1973589?dopt=AbstractPlus</p><p>125. Griggs TR, Wagner GS, Gettes LS. Beta-adrenergic blocking agents after myocardial infarction: an undocumented need in patients at lowest risk. <i>J Am Coll Cardiol</i>. 1983; 1(Suppl 6):1530-3. http://www.ncbi.nlm.nih.gov/pubmed/6133891?dopt=AbstractPlus</p><p>126. Pedersen TR for the Norwegian Multicenter Study Group. Six-year follow-up of the Norwegian multicenter study on timolol after myocardial infarction. <i>N Engl J Med</i>. 1986; 314:1052.</p><p>127. Dalessio DJ. β-Blockers and migraine. <i>JAMA</i>. 1984; 252:2614. http://www.ncbi.nlm.nih.gov/pubmed/6149322?dopt=AbstractPlus</p><p>128. Hart LL. Beta-blocking agents for migraine. <i>DICP</i>. 1989; 23:248-9.</p><p>129. Frishman WH, Furberg CD, Friedewald WT. β-Adrenergic blockade for survivors of acute myocardial infarction. <i>N Engl J Med</i>. 1984; 310:830-7. http://www.ncbi.nlm.nih.gov/pubmed/6142420?dopt=AbstractPlus</p><p>130. Roberts R, Rogers WJ, Mueller H et al. Immediate versus deferred β-blockade following thrombolytic therapy in patients with acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) II-B study. <i>Circulation</i>. 1991; 83:422-37. http://www.ncbi.nlm.nih.gov/pubmed/1671346?dopt=AbstractPlus</p><p>131. Reviewers’ comments (personal observations).</p><p>133. Weber MA, Laragh JH. Hypertension: steps forward and steps backward: the Joint National Committee fifth report. <i>Arch Intern Med</i>. 1993; 153:149-52. http://www.ncbi.nlm.nih.gov/pubmed/8422205?dopt=AbstractPlus</p><p>134. Collins R, Peto R, MacMahon S et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: an overview of randomized drug trials in their epidemiological context. <i>Lancet</i>. 1990; 335:827-38. http://www.ncbi.nlm.nih.gov/pubmed/1969567?dopt=AbstractPlus</p><p>135. Alderman MH. Which antihypertensive drugs first—and why! <i>JAMA</i>. 1992; 267:2786-7. Editorial.</p><p>136. MacMahon S, Peto R, Cutler J et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. <i>Lancet</i>. 1990; 335:765-74. http://www.ncbi.nlm.nih.gov/pubmed/1969518?dopt=AbstractPlus</p><p>137. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). <i>JAMA</i>. 1991; 265:3255-64. http://www.ncbi.nlm.nih.gov/pubmed/2046107?dopt=AbstractPlus</p><p>138. Dahlof B, Lindholm LH, Hansson L et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-hypertension). <i>Lancet</i>. 1991; 338:1281-5. http://www.ncbi.nlm.nih.gov/pubmed/1682683?dopt=AbstractPlus</p><p>139. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. <i>BMJ</i>. 1992; 304:405-12. http://www.ncbi.nlm.nih.gov/pubmed/1445513?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=1995577&amp;blobtype=pdf</p><p>141. Kaplan NM. Choice of initial therapy for hypertension. <i>JAMA</i>. 1996; 275:1577-80. http://www.ncbi.nlm.nih.gov/pubmed/8622249?dopt=AbstractPlus</p><p>142. Psaty BM, Smith NL, Siscovich DS et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. <i>JAMA</i>. 1997; 277:739-45. http://www.ncbi.nlm.nih.gov/pubmed/9042847?dopt=AbstractPlus</p><p>144. Whelton PK, Appel LJ, Espeland MA et al. for the TONE Collaborative Research Group. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). <i>JAMA</i>. 1998; 279:839-46. http://www.ncbi.nlm.nih.gov/pubmed/9515998?dopt=AbstractPlus</p><p>145. Merck &amp; Co. Blocadren<sup></sup> (timolol maleate) tablets prescribing information (dated 1997 Nov). In: Physicians’ desk reference. 52nd ed. Montvale, NJ: Medical Economics Company Inc; 1998(Suppl A):A204-5.</p><p>146. Clonidine/beta blockers. In: Tatro DS, Olin BR, Hebel SK, eds. Drug interaction facts. St. Louis: JB Lippincott Co; 1992 (July):200.</p><p>148. Genuth P. United Kingdom prospective diabetes study results are in. <i>J Fam Pract</i>. 1998; 47:(Suppl 5):S27.</p><p>150. Watkins PJ. UKPDS: a message of hope and a need for change. <i>Diabet Med</i>. 1998; 15:895-6. http://www.ncbi.nlm.nih.gov/pubmed/9827842?dopt=AbstractPlus</p><p>151. Bretzel RG, Voit K, Schatz H et al. The United Kingdom Prospective Diabetes Study (UKPDS): implications for the pharmacotherapy of type 2 diabetes mellitus. <i>Exp Clin Endocrinol Diabetes</i>. 1998; 106:369-72. http://www.ncbi.nlm.nih.gov/pubmed/9831300?dopt=AbstractPlus</p><p>152. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. <i>BMJ</i>. 1998; 317:703-13. http://www.ncbi.nlm.nih.gov/pubmed/9732337?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=28659&amp;blobtype=pdf</p><p>153. American Diabetes Association. The United Kingdom Prospective Diabetes Study (UKPDS) for type 2 diabetes: what you need to know about the results of a long-term study. Washington, DC; 1998 Sep 15. From American Diabetes Association web site. http://www.diabetes.org</p><p>154. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular complications in type 2 diabetes: UKPDS 39. <i>BMJ</i>. 1998; 317:713-20. http://www.ncbi.nlm.nih.gov/pubmed/9732338?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=28660&amp;blobtype=pdf</p><p>155. Davis TME. United Kingdom Prospective Diabetes Study: the end of the beginning? <i>Med J Aust</i>. 1998; 169:511-2.</p><p>157. Anon. Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. Part II. Management of heart failure: apporaches to the prevention of heart failure. <i>Am J Cardiol</i>. 1999; 83:9-38A.</p><p>159. Lim PO, MacDonald TM. Antianginal and β-adrenergic blocking drugs. In: Dukes MNG, ed. Meyler’s side effects of drugs. 13th ed. New York: Elsevier/North Holland Inc; 1996:488-535.</p><p>160. Gress TW, Nieto FJ, Shahar E et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. <i>N Engl J Med</i>. 2000; 342:905-12. http://www.ncbi.nlm.nih.gov/pubmed/10738048?dopt=AbstractPlus</p><p>161. Sowers JR, Bakris GL. Antihypertensive therapy and the risk of type 2 diabetes mellitus. <i>N Engl J Med</i>. 2000; 342:969-70. http://www.ncbi.nlm.nih.gov/pubmed/10738057?dopt=AbstractPlus</p><p>162. Izzo JL, Levy D, Black HR. Importance of systolic blood pressure in older Americans. <i>Hypertension</i>. 2000; 35:1021-4. http://www.ncbi.nlm.nih.gov/pubmed/10818056?dopt=AbstractPlus</p><p>163. Frohlich ED. Recognition of systolic hypertension for hypertension. <i>Hypertension</i>. 2000; 35:1019-20. http://www.ncbi.nlm.nih.gov/pubmed/10818055?dopt=AbstractPlus</p><p>164. Bakris GL, Williams M, Dworkin L et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. <i>Am J Kidney Dis</i>. 2000; 36:646-61. http://www.ncbi.nlm.nih.gov/pubmed/10977801?dopt=AbstractPlus</p><p>165. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. <i>Lancet</i>. 1998; 351:1755-62. http://www.ncbi.nlm.nih.gov/pubmed/9635947?dopt=AbstractPlus</p><p>168. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Chronic Stable Angina). <i>J Am Coll Cardiol</i>. 1999; 33:2092-7.</p><p>170. Williams CL, Hayman LL, Daniels SR et al. Cardiovascular health in childhood: a statement for health professional from the Committee on Atherosclerosis, Hypertension, and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the Young, American Heart Association. <i>Circulation</i>. 2002; 106:143-60. http://www.ncbi.nlm.nih.gov/pubmed/12093785?dopt=AbstractPlus</p><p>171. Ramadan NM, Silberstein SD, Freitag FG et al. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management for prevention of migraine. St. Paul, MN; 2001. From the American Academy of Neurology web site. http://www.aan.com</p><p>173. Appel LJ. The verdict from ALLHAT—thiazide diuretics are the preferred initial therapy for hypertension. <i>JAMA</i>. 2002; 288:3039-42. http://www.ncbi.nlm.nih.gov/pubmed/12479770?dopt=AbstractPlus</p><p>174. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-riskhypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). <i>JAMA</i>. 2002; 288:2981-97. http://www.ncbi.nlm.nih.gov/pubmed/12479763?dopt=AbstractPlus</p><p>176. Douglas JG, Bakris GL, Epstein M et al. Management of high blood pressure in African Americans: Consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med. 2003; 163:525-41.</p><p>178. The Guidelines Subcommitee of the WHO/ISH Mild Hypertension Liaison Committee. 1999 guidelines for the management of hypertension. <i>J Hypertension</i>. 1999; 17:392-403.</p><p>180. Wright JT, Dunn JK, Cutler JA et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. <i>JAMA</i>. 2005; 293:1595-607. http://www.ncbi.nlm.nih.gov/pubmed/15811979?dopt=AbstractPlus</p><p>181. Neaton JD, Kuller LH. Diuretics are color blind. <i>JAMA</i>. 2005; 293:1663-6. http://www.ncbi.nlm.nih.gov/pubmed/15811986?dopt=AbstractPlus</p><p>182. Thadani U. Beta blockers in hypertension. <i>Am J Cardiol</i>. 1983; 52:10-5D.</p><p>183. Conolly ME, Kersting F, Dollery CT. The clinical pharmacology of beta-adrenoceptor-blocking drugs. <i>Prog Cardiovasc Dis</i>. 1976; 19:203-34. http://www.ncbi.nlm.nih.gov/pubmed/10600?dopt=AbstractPlus</p><p>184. Shand DG. State-of-the-art: comparative pharmacology of the β-adrenoceptor blocking drugs. <i>Drugs</i>. 1983; 25(Suppl 2):92-9.</p><p>185. Breckenridge A. Which beta blocker? <i>Br Med J</i>. 1983; 286:1085-8. (IDIS 169422)</p><p>186. Anon. Choice of a beta-blocker. <i>Med Lett Drugs Ther</i>. 1986; 28:20-2. http://www.ncbi.nlm.nih.gov/pubmed/2869400?dopt=AbstractPlus</p><p>187. Wallin JD, Shah SV. β-Adrenergic blocking agents in the treatment of hypertension: choices based on pharmacological properties and patient characteristics. <i>Arch Intern Med</i>. 1987; 147:654-9. http://www.ncbi.nlm.nih.gov/pubmed/2881524?dopt=AbstractPlus</p><p>188. McDevitt DG. β-Adrenoceptor blocking drugs and partial agonist activity: is it clinically relevant? <i>Drugs</i>. 1983; 25:331-8.</p><p>189. McDevitt DG. Clinical significance of cardioselectivity: state-of-the-art. <i>Drugs</i>. 1983; 25(Suppl 2):219-26.</p><p>190. Frishman WH. β-Adrenoceptor antagonists: new drugs and new indications. <i>N Engl J Med</i>. 1981; 305:500-6. http://www.ncbi.nlm.nih.gov/pubmed/6114433?dopt=AbstractPlus</p><p>191. Thadani U, Davidson C, Chir B et al. Comparison of the immediate effects of five β-adrenoceptor-blocking drugs with different ancillary properties in angina pectoris. <i>N Engl J Med</i>. 1979; 300:750-5. http://www.ncbi.nlm.nih.gov/pubmed/581782?dopt=AbstractPlus</p><p>192. Lewis RV, McDevitt DG. Adverse reactions and interactions with β-adrenoceptor blocking drugs. <i>Med Toxicol</i>. 1986; 1:343-61. http://www.ncbi.nlm.nih.gov/pubmed/2878346?dopt=AbstractPlus</p><p>193. Frishman WH. Clinical differences between beta-adrenergic blocking agents: implications for therapeutic substitution. <i>Am Heart J</i>. 1987; 113:1190-8. http://www.ncbi.nlm.nih.gov/pubmed/2883867?dopt=AbstractPlus</p><p>194. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. <i>Lancet</i>. 2002;359:995-1003.</p><p>500. National Heart, Lung, and Blood Institute National High Blood Pressure Education Program. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). Bethesda, MD: National Institutes of Health; 2004 Aug. (NIH publication No. 04-5230.)</p><p>501. James PA, Oparil S, Carter BL et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). <i>JAMA</i>. 2014; 311:507-20. http://www.ncbi.nlm.nih.gov/pubmed/24352797?dopt=AbstractPlus</p><p>502. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). <i>J Hypertens</i>. 2013; 31:1281-357. http://www.ncbi.nlm.nih.gov/pubmed/23817082?dopt=AbstractPlus</p><p>503. Go AS, Bauman MA, Coleman King SM et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. <i>Hypertension</i>. 2014; 63:878-85. http://www.ncbi.nlm.nih.gov/pubmed/24243703?dopt=AbstractPlus</p><p>504. Weber MA, Schiffrin EL, White WB et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. <i>J Clin Hypertens (Greenwich)</i>. 2014; 16:14-26. http://www.ncbi.nlm.nih.gov/pubmed/24341872?dopt=AbstractPlus</p><p>505. Wright JT, Fine LJ, Lackland DT et al. Evidence supporting a systolic blood pressure goal of less than 150 mm Hg in patients aged 60 years or older: the minority view. <i>Ann Intern Med</i>. 2014; 160:499-503. http://www.ncbi.nlm.nih.gov/pubmed/24424788?dopt=AbstractPlus</p><p>506. Mitka M. Groups spar over new hypertension guidelines. <i>JAMA</i>. 2014; 311:663-4. http://www.ncbi.nlm.nih.gov/pubmed/24549531?dopt=AbstractPlus</p><p>507. Peterson ED, Gaziano JM, Greenland P. Recommendations for treating hypertension: what are the right goals and purposes?. <i>JAMA</i>. 2014; 311:474-6. http://www.ncbi.nlm.nih.gov/pubmed/24352710?dopt=AbstractPlus</p><p>508. Bauchner H, Fontanarosa PB, Golub RM. Updated guidelines for management of high blood pressure: recommendations, review, and responsibility. <i>JAMA</i>. 2014; 311:477-8. http://www.ncbi.nlm.nih.gov/pubmed/24352759?dopt=AbstractPlus</p><p>515. Thomas G, Shishehbor M, Brill D et al. New hypertension guidelines: one size fits most?. <i>Cleve Clin J Med</i>. 2014; 81:178-88. http://www.ncbi.nlm.nih.gov/pubmed/24591473?dopt=AbstractPlus</p><p>523. Fihn SD, Gardin JM, Abrams J et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. <i>Circulation</i>. 2012; 126:e354-471.</p><p>524. WRITING COMMITTEE MEMBERS, Yancy CW, Jessup M et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. <i>Circulation</i>. 2013; 128:e240-327.</p><p>525. Smith SC, Benjamin EJ, Bonow RO et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. <i>Circulation</i>. 2011; 124:2458-73. http://www.ncbi.nlm.nih.gov/pubmed/22052934?dopt=AbstractPlus</p><p>526. Kernan WN, Ovbiagele B, Black HR et al. Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. <i>Stroke</i>. 2014; :. http://www.ncbi.nlm.nih.gov/pubmed/24788967?dopt=AbstractPlus</p><p>527. O'Gara PT, Kushner FG, Ascheim DD et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2013; 127:e362-425. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=3695607&amp;blobtype=pdf</p><p>530. Myers MG, Tobe SW. A Canadian perspective on the Eighth Joint National Committee (JNC 8) hypertension guidelines. <i>J Clin Hypertens (Greenwich)</i>. 2014; 16:246-8. http://www.ncbi.nlm.nih.gov/pubmed/24641124?dopt=AbstractPlus</p><p>540. Ishii Y, Nakamura K, Tsutsumi K et al. Drug interaction between cimetidine and timolol ophthalmic solution: effect on heart rate and intraocular pressure in healthy Japanese volunteers. <i>J Clin Pharmacol</i>. 2000; 40:193-9. http://www.ncbi.nlm.nih.gov/pubmed/10664926?dopt=AbstractPlus</p><p>536. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. <i>Kidney Int Suppl</i>. 2012: 2: 337-414.</p><p>600. Mylan Pharmaceuticals. Timolol tablets prescribing information. Morgantown, WV; 2006 Aug.</p><p>800. Yancy CW, Jessup M, Bozkurt B et al. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. <i>Circulation</i>. 2016; :.</p><p>802. Bockstall K, Bangalore S. How long should we continue beta-blockers after MI? 2017 Jan 23. From ACC website. Accessed 2017 May 17. http://www.acc.org/latest-in-cardiology/articles/2017/01/20/09/36/how-long-should-we-continue-beta-blockers-after-mi</p><p>804. Kezerashvili A, Marzo K, De Leon J. Beta blocker use after acute myocardial infarction in the patient with normal systolic function: when is it “ok” to discontinue?. <i>Curr Cardiol Rev</i>. 2012; 8:77-84. http://www.ncbi.nlm.nih.gov/pubmed/22845818?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=3394111&amp;blobtype=pdf</p><p>806. Freemantle N, Cleland J, Young P et al. beta Blockade after myocardial infarction: systematic review and meta regression analysis. <i>BMJ</i>. 1999; 318:1730-7. http://www.ncbi.nlm.nih.gov/pubmed/10381708?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=31101&amp;blobtype=pdf</p><p>1101. Fihn SD, Gardin JM, Abrams J et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. <i>Circulation</i>. 2012; 126:e354-471.</p><p>1200. Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Hypertension</i>. 2018; 71:el13-e115. http://www.ncbi.nlm.nih.gov/pubmed/29133356?dopt=AbstractPlus</p><p>1201. Bakris G, Sorrentino M. Redefining hypertension - assessing the new blood-pressure guidelines. <i>N Engl J Med</i>. 2018; 378:497-499. http://www.ncbi.nlm.nih.gov/pubmed/29341841?dopt=AbstractPlus</p><p>1202. Carey RM, Whelton PK, 2017 ACC/AHA Hypertension Guideline Writing Committee. Prevention, detection, evaluation, and management of high blood pressure in adults: synopsis of the 2017 American College of Cardiology/American Heart Association hypertension guideline. <i>Ann Intern Med</i>. 2018; 168:351-358. http://www.ncbi.nlm.nih.gov/pubmed/29357392?dopt=AbstractPlus</p><p>1207. Burnier M, Oparil S, Narkiewicz K et al. New 2017 American Heart Association and American College of Cardiology guideline for hypertension in the adults: major paradigm shifts, but will they help to fight against the hypertension disease burden?. <i>Blood Press</i>. 2018; 27:62-65. http://www.ncbi.nlm.nih.gov/pubmed/29447001?dopt=AbstractPlus</p><p>1209. Qaseem A, Wilt TJ, Rich R et al. Pharmacologic treatment of hypertension in adults aged 60 years or older to higher versus lower blood pressure targets: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. <i>Ann Intern Med</i>. 2017; 166:430-437. http://www.ncbi.nlm.nih.gov/pubmed/28135725?dopt=AbstractPlus</p><p>1210. SPRINT Research Group, Wright JT, Williamson JD et al. A randomized trial of intensive versus standard blood-pressure control. <i>N Engl J Med</i>. 2015; 373:2103-16. http://www.ncbi.nlm.nih.gov/pubmed/26551272?dopt=AbstractPlus</p><p>1216. Taler SJ. Initial treatment of hypertension. <i>N Engl J Med</i>. 2018; 378:636-644. http://www.ncbi.nlm.nih.gov/pubmed/29443671?dopt=AbstractPlus</p><p>1220. Cifu AS, Davis AM. Prevention, detection, evaluation, and management of high blood pressure in adults. <i>JAMA</i>. 2017; 318:2132-2134. http://www.ncbi.nlm.nih.gov/pubmed/29159416?dopt=AbstractPlus</p><p>1222. Bell KJL, Doust J, Glasziou P. Incremental benefits and harms of the 2017 American College of Cardiology/American Heart Association high blood pressure guideline. <i>JAMA Intern Med</i>. 2018; 178:755-7. http://www.ncbi.nlm.nih.gov/pubmed/29710197?dopt=AbstractPlus</p><p>1223. LeFevre M. ACC/AHA hypertension guideline: what is new? what do we do?. <i>Am Fam Physician</i>. 2018; 97(6):372-3. http://www.ncbi.nlm.nih.gov/pubmed/29671534?dopt=AbstractPlus</p><p>1224. Brett AS. New hypertension guideline is released. From NEJM Journal Watch website. Accessed 2018 Jun 18. https://www.jwatch.org/na45778/2017/12/28/nejm-journal-watch-general-medicine-year-review-2017</p><p>1229. Ioannidis JPA. Diagnosis and treatment of hypertension in the 2017 ACC/AHA guidelines and in the real world. <i>JAMA</i>. 2018; 319(2):115-6. http://www.ncbi.nlm.nih.gov/pubmed/29242891?dopt=AbstractPlus</p><p>1235. Mann SJ. Redefining beta-blocker use in hypertension: selecting the right beta-blocker and the right patient. <i>J Am Soc Hypertens</i>. 2017; 11(1):54-65. http://www.ncbi.nlm.nih.gov/pubmed/28057444?dopt=AbstractPlus</p><p>a. AHFS Drug Information 2018. McEvoy GK, ed. Timolol Maleate. American Society of Health-System Pharmacists; 2018:.</p><p>b. Merck &amp; Co. Blocadren<sup></sup> (timolol maleate) tablets prescribing information. Whitehouse Station, NJ; 2002 Mar</p><h2>More about timolol</h2><ul class="more-resources-list more-resources-list-general">
<li>Side Effects</li>
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: non-cardioselective beta blockers</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Timolol &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;span&gt;(Advanced Reading)&lt;/span&gt;&lt;/body&gt;&lt;/html&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li>Timolol &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;span&gt;(FDA)&lt;/span&gt;&lt;/body&gt;&lt;/html&gt;</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Angina</li>
<li>Heart Attack</li>
<li>High Blood Pressure</li>
<li>Migraine Prevention</li>
</ul><p class="ddc-disclaimer-link">Medical Disclaimer</p></body></html>